IP Verse

Use Of Il-17 Antagonists To Inhibit The Progression Of Structural Damage In Psoriatic Arthritis Patients

Patent No. EP3191120 (titled "Use Of Il-17 Antagonists To Inhibit The Progression Of Structural Damage In Psoriatic Arthritis Patients") was filed by Novartis on Sep 8, 2015. The application was issued on Apr 10, 2024.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
GRAF VON STOSCH PATENTANWALTSGESELLSCHAFTJan 10, 2025LEPTHIEN
HAMPTON KNOWLESJan 10, 2025D YOUNG
MAIWALDJan 10, 2025MAIWALD

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3191120

NOVARTIS
Application Number
EP15767597A
Filing Date
Sep 8, 2015
Status
Granted And Under Opposition
Mar 8, 2024
Publication Date
Apr 10, 2024
External Links
Slate, Register , Google Patents